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resources and work productivity were also recorded. RESULTS:
The sample for this analysis was composed of patients treated
with GBP (n = 44) and a random sample of 88 patients treated
with PGB and matched for age, sex, and clinical characteristics.
Mean (SD) doses for GBP and PGB were 1263 (540) and 202
(119) mg/day, respectively. Patients treated with PGB showed
greater reduction in pain intensity compared with GBP patients
(39  23 vs 28  22 mm in the VAS SF-MPQ; p = 0.008), yield-
ing to a higher signiﬁcantly proportion of patients with a 50%
reduction of baseline pain at the end of the study; 41% vs. 61%,
respectively; p = 0.029. The remaining patient-reported out-
comes improved signiﬁcantly and to a similar extent after treat-
ment with either drug. The signiﬁcantly higher drug cost of PGB
as compared with GBP was traded-off with the greater reduction
in productivity cost in the former group. CONCLUSIONS: Both
drugs were associated with a similar reduction of costs. However,
results suggest that pregabalin showed a greater effectiveness
than gabapentin in the control of NeP. These differences may
reﬂect greater difﬁculties in reaching the therapeutic dose for
gabapentin in routine medical practice.
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OBJECTIVES: One of the challenges for innovation in chronic
pain treatment is to provide consistent pain control over a 24-hour
period. How does this clinical objective translate into concepts
relevant to patients, and do the existing instruments adequately
capture these concepts? METHODS: Thirty face-to-face explor-
atory interviews were conducted by psychologists in France,
Germany and the UK with patients with chronic pain (cancer-
related pain excluded) to collect information on how they describe
the course of pain over 24 hours and how changes in pain levels
and the time they occur affects their everyday lives. In parallel, a
list of related concepts and a description of the conceptual con-
tents of existing instruments was extracted from the literature.
RESULTS: Analysis of the patient interviews resulted in the
identiﬁcation of several concepts related to 24-hour pain control
which are closely intertwined with one another: type of pain
(background, breakthrough, and end-of-dose pain), description
(occurrence, intensity, sensation), worsening, relieving, triggering
factors, impact of pain (particularly patients’ activities of daily
living, sleep andmood), pain medication (efﬁcacy, time to efﬁcacy,
duration of efﬁcacy, frequency medication is taken) and pain over
time (evolution over one day).Most of these concepts are partially
or extensively covered by existing instruments. However, no
instrument is comprehensive enough to be used as a standalone
measure. CONCLUSIONS: The control of 24-hour pain is
complex and requires multidimensional assessment. Despite the
considerable number of pain questionnaires available, no speciﬁc
measurement instrument exists that fully addresses the concerns
of patients. To accurately capture the beneﬁts of once-daily treat-
ments in pain control, researchers need either a new instrument, or
the adaptation of a series of existing questionnaires to form a
consistent and comprehensive battery.
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OBJECTIVES: To analyze prospectively the effect of adding Pre-
gabalin (PGB) on PRO measurements evolution in the treatment
of refractory Low Back Pain under routine medical practice
conditions. METHODS: Post-hoc analysis of patients above 18
years, with 6-month chronic Low Back pain refractory to, at
least, one previous analgesic [previous mean (SD) number of
drugs was 2.1 (1.3), 22.7% on one-drug], included in a prospec-
tive, naturalistic, 12-weeks two-visit study. This analysis com-
pared patients receiving PGB as an add-on therapy (PGB add-on)
versus subjects receiving any other analgesic pattern not includ-
ing PGB (non-PGB). PRO measurements included evaluation of
severity and interference of pain (Brief Pain Inventory), anxiety
and depression symptoms (HAD scale), and quality-of-life (SF-
12). RESULTS: A total of 683 [49.5% women, 55.0 (12.7) years]
patients were analyzed: 82.6% received PGB add-on and 17.4%
non-PGB. Twelve weeks therapy with PGB add-on was associ-
ated with higher reduction in pain severity than in non-PGB; -3.4
(2.0) pts, 61.6% responders (350% baseline pain reduction) vs.
-2.0 (2.1), 37.3% responders; p < 0.0001, respectively. Pain
interference was also reduced more with PGB add-on: -3.5 (2.1)
pts vs. -2.0 (2.3), respectively; p < 0.0001, and showed greater
reduction in depression [-4.0 (4.1) pts vs. -2.1 (3.3); p < 0.0001]
and anxiety [-3.7 (3.6) pts vs. -1.9 (3.0); p < 0.0001] symptoms
scores, yielding to a signiﬁcant improvement in patient’s quality
of life: mental and physical summary components change were
higher in PGB add-on therapy group: +7.3 (10.6) vs. +2.0 (7.4);
p < 0.0001, and +9.7 (9.6) vs. +5.8 (8.3); p < 0.0001, respec-
tively. CONCLUSIONS: Compared with adding other any drug,
the addition of PGB to the treatment pattern of refractory Low
Back Pain seems to be associated with higher improvement in
PRO measurements, including reduction of pain severity and
interference and improvement of quality of life under routine
medical practice condition.
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OBJECTIVES: The Government of Russian Federation provided
up to US$377 million to the management of hereditary coagulo-
pathies (hemophilia type A and type B, von Willebrand’s disease)
since 2008. The amount of ﬁnancing to the custom of coagula-
tion factors increased 20 times for 2004–2008, and at
the present, aggregate 3.49 IU of clotting factor VIII fall on one
citizen of Russia. Russian Society of Pharmacoeconomics and
Outcomes Research jointly with the All-Russian Hemophilia
Society made the ﬁrst Russian postal survey of all registered
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Russian patients with hereditary coagulopathies to determine
quality of life. METHODS: Postal survey of 6309 patients using
EUROQoL-5D (EQ-5D) was made in December 2007–January
2008. The questionnaire was proposed to all registered patients
suffer from hereditary coagulopathies from 12 years old. The
data of ﬁve dimensions of the questionnaire (mobility, self-care,
usual activities, pain/discomfort anxiety/depression) and data
from the visual-analog scale was analyzed. RESULTS: A total of
1030 (16.3%) completed questionnaires were received by May
11, 2008. Forty-eight questionnaires were excluded from analy-
sis because of the absence of key elements. Data of 472 adult and
children 12 years old were analyzed; 462 questionnaires are
under analyses now. A total of 661 (10.5%) blank questionnaires
returned (due to death, changing place of living). A total of
67.1% of patients reported any problems (moderate or severe)
with mobility (no information about 1.5% of patients), 36.4% of
patients inform of any problems with self-care (no data about
1.3% of patients). A total of 63.6% of patients had difﬁculties
with usual activity (no data about 0.7% of patients). A total of
81.4% of patients report of presence of pain and discomfort (no
data about 0.8% of patients). A total 52.1% of patients report of
anxiety or depression (no information about 2.3% of patients).
The average value of quality of life according to the visual-analog
scale was 57.47. CONCLUSIONS: The intermediate results
of postal survey, investigating a quality of life in Russian
patients with hereditary coagulopathies, shows high rate of
problems with mobility, usual activity and high rate of pain and
discomfort.
PSY53
SATISFACTION WITH IRON CHELATIONTHERAPY IS
ASSOCIATED WITH IMPROVED QUALITY OF LIFE IN
PATIENTS WITH IRON OVERLOAD
Rofail D1,Abetz L1, Heelis R1, Baladi JF2
1Mapi Values, Bollington, Cheshire, UK, 2Novartis Pharmaceuticals
Corp, Florham Park, NJ, USA
OBJECTIVES: Traditional iron overload treatment can be very
time-consuming for the patient, making it important to augment
clinical assessments with patient-reported outcomes. This study
investigated the link between satisfaction with ICT and health-
related quality of life (HRQoL). METHODS: As part of a ret-
rospective chart review and semi-prospective investigation,
patients with thalassaemia (n = 81), sickle cell disease (n = 23),
or myelodysplastic syndromes (n = 6) from eight study sites (four
per country: US (n = 60) and UK (n = 50)) completed the Satis-
faction with ICT instrument (SICT) and the Short Form 36-Item
Health Survey (SF-36) at one study visit. Patients were receiving
deferoxamine, deferiprone, or combined therapy. To explore the
associations between satisfaction and HRQoL, Pearson’s corre-
lation coefﬁcients were calculated between the SICT and SF-36.
A statistical signiﬁcant level of p  0.05 was applied. RESULTS:
Data from 110 iron overload patients undergoing ICT partici-
pated in the study (female 57.27% (n = 63); mean age 30.9
years). The SICT ‘Burden of ICT’ and ‘Side Effects of ICT’
domains signiﬁcantly correlated with all SF-36 domain and
summary scores (r = 0.29 to 0.45 and r = 0.21 to 0.41, respec-
tively) with the exception of ‘Side Effects of ICT’ and ‘Role-
Physical’ (r = 0.19). The SICT ‘Perceived Effectiveness of ICT’
domain signiﬁcantly correlated with SF-36 domains ‘General
Health’ (r = 0.23) and ‘Social Functioning’ (r = 0.24), whilst
‘Acceptability of ICT’ correlated with ‘Bodily Pain’ (r = 0.22)
and ‘General Health’ (r = 0.22). CONCLUSIONS: Satisfaction
with ICT provides prognostic information beyond standard clini-
cal and physiological assessments. Results indicated that as ICT
burden and side effects decreased, HRQoL increased. Further
research is warranted using clinical trial data to validate these
results. Clear a priori hypothesis could be developed and tested
using regressions or structural equation modelling.
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OBJECTIVES: To understand patients’ tolerability and per-
ception of the effectiveness of the BIB system. METHODS: A
paper-based survey was completed by 186 patients through 5
physician’s practices in Europe, Canada and South America.
Surveys were completed either in person or via phone by a health
care professional. Questions focused on patient demographics,
current or prior use of the BIB system, self reported weight loss,
and tolerability. Univariate analyses were performed to evaluate
the amount of weight loss, side effects associated with the BIB
system, patients’ overall satisfaction with the system, and the
likelihood of recommending it to others. RESULTS: Of the 186
respondents, 40% were currently using the BIB system. The
mean age of the population was 37 years (range 17–76 years).
The average weight loss for patients who had completed the full
6 months at the time of the survey was 17.7 kg. While during the
induction phase of using the BIB system, the majority of patients
experienced moderate to severe nausea and vomiting, but their
daily functioning was not greatly affected. While using the BIB
system, more than half of the patients experienced nausea,
cramping, and vomiting; however, most patients had complete
resolution of symptoms within 7 days. About 87% of the
patients were satisﬁed with the BIB system and 85% would
recommend it to others. Reasons for satisfaction included:
amount of weight loss and ability to effectively diet without
feeling hungry. CONCLUSIONS: Most patients were satisﬁed
with the BIB system, despite early side effects they experienced,
and would consequently recommend BIB to others.
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OBJECTIVES: To explore the perspectives of both physicians
and patients on how pain was assessed, managed and treated.
METHODS: Face to face semi-structured questionnaires were
administered with 70 physicians and 210 patients. Most of the
physicians were specialists (78.6%) and practiced at private hos-
pitals (61%). Patients were recruited through the physicians at
their consultation. RESULTS: Most patients were female (71%)
and aged less than 30 years were seen by GPs while the older ones
41–60 years, were seen by specialists. Lumbar/low back pain and
osteoarthritis were the most common pain encountered and one-
third of the patients suffered from pain for less than three weeks
before seeing doctors. Overall the patients were quite satisﬁed
with their doctors’ consultation time spent. However, the patients
who were treated by GPs perceived that their doctors did not
explain about the treatment options to the same level as physicians
claimed that their patients were informed. Regarding the types of
treatment, 93%physicians reported that they likely recommended
both pharmacological and non-pharmacological treatments but
the patients revealed that they received pharmacological treat-
ment only (47%) and 53% for the combination remedy. Factors
A646 Abstracts
